Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates

Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelled somatostatin analogues is a procedure with multiple steps. We present the SPECT/CT-based implementation at Aarhus University Hospital and evaluate the uncertainty of the various steps in order to es...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peter Frøhlich Staanum, Anders Floor Frellsen, Marie Louise Olesen, Peter Iversen, Anne Kirstine Arveschoug
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	PRRT Peptide receptor radionuclide therapy Kidney dosimetry Lu-177 Lu-DOTATOC Lu-DOTATATE Medical physics. Medical radiology. Nuclear medicine R895-920
Acceso en línea:	https://doaj.org/article/0310ebdbca504a1180a77a2a6d0530af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0310ebdbca504a1180a77a2a6d0530af
record_format	dspace
spelling	oai:doaj.org-article:0310ebdbca504a1180a77a2a6d0530af2021-11-14T12:27:12ZPractical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates10.1186/s40658-021-00422-22197-7364https://doaj.org/article/0310ebdbca504a1180a77a2a6d0530af2021-11-01T00:00:00Zhttps://doi.org/10.1186/s40658-021-00422-2https://doaj.org/toc/2197-7364Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelled somatostatin analogues is a procedure with multiple steps. We present the SPECT/CT-based implementation at Aarhus University Hospital and evaluate the uncertainty of the various steps in order to estimate the total uncertainty and to identify the major sources of uncertainty. Absorbed dose data from 115 treatment fractions are reported. Results The total absorbed dose with uncertainty is presented for 59 treatments with [177Lu]Lu-DOTATOC and 56 treatments with [177Lu]Lu-DOTATATE. For [177Lu]Lu-DOTATOC the mean and median specific absorbed dose (dose per injected activity) is 0.37 Gy/GBq and 0.38 Gy/GBq, respectively, while for [177Lu]Lu-DOTATATE the median and mean are 0.47 Gy/GBq and 0.46 Gy/GBq, respectively. The uncertainty of the procedure is estimated to be about 13% for a single treatment fraction, where the absorbed dose calculation is based on three SPECT/CT scans 1, 4 and 7 days post-injection, while it increases to about 19% if only a single SPECT/CT scan is performed 1 day post-injection. Conclusions The specific absorbed dose values obtained with the described procedure are comparable to those from other treatment sites for both [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE, but towards the lower end of the range of reported values. The estimated uncertainty is also comparable to that from other reports and judged acceptable for clinical and research use, thus proving the kidney dosimetry procedure a useful tool. The greatest reduction in uncertainty can be obtained by improved activity determination, partial volume correction and additional SPECT/CT scans.Peter Frøhlich StaanumAnders Floor FrellsenMarie Louise OlesenPeter IversenAnne Kirstine ArveschougSpringerOpenarticlePRRTPeptide receptor radionuclide therapyKidney dosimetryLu-177Lu-DOTATOCLu-DOTATATEMedical physics. Medical radiology. Nuclear medicineR895-920ENEJNMMI Physics, Vol 8, Iss 1, Pp 1-25 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PRRT Peptide receptor radionuclide therapy Kidney dosimetry Lu-177 Lu-DOTATOC Lu-DOTATATE Medical physics. Medical radiology. Nuclear medicine R895-920
spellingShingle	PRRT Peptide receptor radionuclide therapy Kidney dosimetry Lu-177 Lu-DOTATOC Lu-DOTATATE Medical physics. Medical radiology. Nuclear medicine R895-920 Peter Frøhlich Staanum Anders Floor Frellsen Marie Louise Olesen Peter Iversen Anne Kirstine Arveschoug Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
description	Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelled somatostatin analogues is a procedure with multiple steps. We present the SPECT/CT-based implementation at Aarhus University Hospital and evaluate the uncertainty of the various steps in order to estimate the total uncertainty and to identify the major sources of uncertainty. Absorbed dose data from 115 treatment fractions are reported. Results The total absorbed dose with uncertainty is presented for 59 treatments with [177Lu]Lu-DOTATOC and 56 treatments with [177Lu]Lu-DOTATATE. For [177Lu]Lu-DOTATOC the mean and median specific absorbed dose (dose per injected activity) is 0.37 Gy/GBq and 0.38 Gy/GBq, respectively, while for [177Lu]Lu-DOTATATE the median and mean are 0.47 Gy/GBq and 0.46 Gy/GBq, respectively. The uncertainty of the procedure is estimated to be about 13% for a single treatment fraction, where the absorbed dose calculation is based on three SPECT/CT scans 1, 4 and 7 days post-injection, while it increases to about 19% if only a single SPECT/CT scan is performed 1 day post-injection. Conclusions The specific absorbed dose values obtained with the described procedure are comparable to those from other treatment sites for both [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE, but towards the lower end of the range of reported values. The estimated uncertainty is also comparable to that from other reports and judged acceptable for clinical and research use, thus proving the kidney dosimetry procedure a useful tool. The greatest reduction in uncertainty can be obtained by improved activity determination, partial volume correction and additional SPECT/CT scans.
format	article
author	Peter Frøhlich Staanum Anders Floor Frellsen Marie Louise Olesen Peter Iversen Anne Kirstine Arveschoug
author_facet	Peter Frøhlich Staanum Anders Floor Frellsen Marie Louise Olesen Peter Iversen Anne Kirstine Arveschoug
author_sort	Peter Frøhlich Staanum
title	Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
title_short	Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
title_full	Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
title_fullStr	Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
title_full_unstemmed	Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
title_sort	practical kidney dosimetry in peptide receptor radionuclide therapy using [177lu]lu-dotatoc and [177lu]lu-dotatate with focus on uncertainty estimates
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/0310ebdbca504a1180a77a2a6d0530af
work_keys_str_mv	AT peterfrøhlichstaanum practicalkidneydosimetryinpeptidereceptorradionuclidetherapyusing177luludotatocand177luludotatatewithfocusonuncertaintyestimates AT andersfloorfrellsen practicalkidneydosimetryinpeptidereceptorradionuclidetherapyusing177luludotatocand177luludotatatewithfocusonuncertaintyestimates AT marielouiseolesen practicalkidneydosimetryinpeptidereceptorradionuclidetherapyusing177luludotatocand177luludotatatewithfocusonuncertaintyestimates AT peteriversen practicalkidneydosimetryinpeptidereceptorradionuclidetherapyusing177luludotatocand177luludotatatewithfocusonuncertaintyestimates AT annekirstinearveschoug practicalkidneydosimetryinpeptidereceptorradionuclidetherapyusing177luludotatocand177luludotatatewithfocusonuncertaintyestimates
_version_	1718429207425449984

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates

Ejemplares similares